Free Newsletter
Takeda expands R&D budget, may look for buyout
Japan's Takeda plans to significantly raise the amount of money it is investing in R&D, according to a report in a Japanese newspaper. The drug developer says it will spend 20 percent of its revenue from drug sales, or about $8.6 billion, on research over the next five years. And it will consider an acquisition to help boost its pipeline. New drug candidates are essential for Takeda, which is facing the loss of patents for drugs that supply 60 percent of its revenue. Takeda recently shuttered development of a new compound to replace Actos for diabetes.
- read the report from MarketWatch on Takeda's plans
Be the first to comment
More stories about Takeda Japan patents pharmaceuticals drug developer drug candidates Mergers and Acqusitions Diabetes pipeline
Comments
By smjacob | Posted 6:39pm | August 5, 2007
An acquisition would be the smartest move in the given situation since it could greatly help to boost the companies profits. A good choice from Takeda would be a retailer, although it is not "familiar ground". And the highest growing retailers in the pharmaceutical sector are the pharmacy online companies.
